Published in Oncologist on September 20, 2011
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol (2015) 1.48
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Mouse models of pancreatic cancer. World J Gastroenterol (2012) 1.20
An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther (2015) 1.14
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer (2014) 1.08
Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol (2015) 1.00
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med (2014) 0.97
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. Sci Rep (2015) 0.95
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res (2013) 0.89
First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. BMC Cancer (2013) 0.88
Identification of germline genetic mutations in patients with pancreatic cancer. Cancer (2015) 0.87
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. J Gastrointest Oncol (2014) 0.84
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Adenocarcinoma of the pancreas. Semin Diagn Pathol (2014) 0.80
Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Curr Oncol (2015) 0.79
Genomic landscapes of pancreatic neoplasia. J Pathol Transl Med (2015) 0.78
The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Biomed Res Int (2016) 0.78
Familial Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am (2015) 0.77
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Rev Gastroenterol Hepatol (2016) 0.76
Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol (2017) 0.75
Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Cell Rep (2016) 0.75
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer (2017) 0.75
Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol (2016) 0.75
Clinical Genetic Testing in Gastroenterology. Clin Transl Gastroenterol (2016) 0.75
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol (2016) 0.75
Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract (2013) 0.75
Genetic factors affecting patient responses to pancreatic cancer treatment. Ann Gastroenterol (2016) 0.75
Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. J Gastrointest Oncol (2016) 0.75
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer (2017) 0.75
Pancreatic Cancer Screening. Curr Treat Options Gastroenterol (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer (2010) 1.32
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol (2011) 1.04
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol (2002) 6.74
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol (2004) 3.08
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg (2010) 2.98
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol (2010) 2.81
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol (2011) 2.42
Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg (2013) 2.29
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg (2007) 2.12
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.11
Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. Ann Surg Oncol (2009) 2.10
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol (2009) 2.07
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol (2008) 2.07
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol (2013) 2.03
Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res (2011) 2.00
Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res (2011) 1.98
Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg (2010) 1.98
Sarcoma. Mayo Clin Proc (2007) 1.94
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology (2012) 1.94
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg (2007) 1.86
Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw (2010) 1.85
Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol (2007) 1.84
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82
Advanced gastric cancer--slow but steady progress. Cancer Treat Rev (2010) 1.79
Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol (2011) 1.75
Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg (2012) 1.71
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res (2010) 1.68
A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support Oncol (2005) 1.65
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer (2010) 1.64
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol (2007) 1.64
BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res (2004) 1.61
Contemporary experience with postpancreatectomy hemorrhage: results of 1,122 patients resected between 2006 and 2011. J Am Coll Surg (2012) 1.58
Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg (2013) 1.58
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg (2011) 1.57
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer (2011) 1.53
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. Cancer (2008) 1.53
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol (2002) 1.50
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg (2007) 1.47
Relative quantification of serum proteins from pancreatic ductal adenocarcinoma patients by stable isotope dilution liquid chromatography-mass spectrometry. J Proteome Res (2012) 1.47
Diagnosing hereditary colorectal cancer. Clin Colorectal Cancer (2010) 1.47
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol (2012) 1.46
Laparoscopic distal pancreatectomy: evolution of a technique at a single institution. J Am Coll Surg (2010) 1.46
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg (2010) 1.43
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol (2003) 1.43
Changes in the management of benign liver tumours: an analysis of 285 patients. HPB (Oxford) (2012) 1.42
MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.42
Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg (2011) 1.41
Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. Genes Cancer (2010) 1.38
Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol (2012) 1.37
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol (2010) 1.37
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36
Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg (2008) 1.36
An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One (2013) 1.33
Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. J Gastrointest Surg (2010) 1.33
Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol (2008) 1.31
Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res (2011) 1.31
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg (2010) 1.31
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer (2008) 1.28
Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One (2010) 1.25
Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev (2007) 1.25
PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. ACS Nano (2008) 1.25
Cancer genomics and inherited risk. J Clin Oncol (2014) 1.24
Endoscopic management of occluded biliary Wallstents: a cancer center experience. Gastrointest Endosc (2003) 1.24
Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol (2007) 1.23
Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer (2010) 1.23